Related Experiment Video
Updated: Aug 14, 2026
07:52
In Vivo Imaging and Tracking of Technetium-99m Labeled Bone Marrow Mesenchymal Stem Cells in Equine Tendinopathy
Published on: December 9, 2015
Technetium-99m-labeled antigranulocyte antibody bone marrow scintigraphy
1Department of Nuclear Medicine, Seoul National University Hospital, Korea.
Summary
99mTc-antigranulocyte antibody (AGA) bone marrow scintigraphy showed high sensitivity (100%) and good specificity (79%) in differentiating malignant from benign skeletal lesions in patients with equivocal bone scans.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Bone scintigraphy is sensitive but lacks specificity for skeletal metastases.
- Differentiating malignant from benign bone lesions can be challenging.
Purpose of the Study:
- To evaluate 99mTc-antigranulocyte antibody (AGA) bone marrow scintigraphy.
- To assess its utility in differentiating malignant from benign skeletal lesions in patients with equivocal bone scans.
Main Methods:
- 42 patients with equivocal bone scans underwent 99mTc-AGA scintigraphy 1 week after 99mTc-MDP bone imaging.
- Scans were assessed for concordant marrow defects.
- Final diagnoses were based on radiological results, follow-up, or clinical evaluation over 12 months.
Main Results:
- Skeletal metastasis was diagnosed in 19 patients, and no metastasis in 20.
- AGA scans showed 100% sensitivity and 79% specificity for skeletal metastases.
- Concordant marrow defects were observed in 17 patients, while 15/19 patients without metastasis had normal AGA scans.
Conclusions:
- 99mTc-AGA bone marrow scintigraphy demonstrated a low incidence of skeletal metastases in patients with equivocal bone scans.
- A concordant marrow defect suggests metastasis, but further investigation is needed to rule out benign conditions.
